drugset / Trial / NCT01059578

First Study in Humans With GSK206136

NCT01059578 ↗

Phase 1 Completed 33 enrolled GlaxoSmithKline
RandomizedCrossoverDouble-blindBasic science

Summary

This is the first study in humans with GSK206136 to evaluate what effects: good or bad, the drug has on human health (safety and tolerability) and the amount of drug which gets into the bloodstream and is eliminated from the body (pharmacokinetics). Also the study aims to investigate the penetration of the drug in the human brain by using PET (Positron Emission Tomography) imaging technology

Timeline

Start
2006-05-23
Primary completion
2006-12-18
Completion
2006-12-18

Drugs

EvaluationDrugModalityDoseRoute
Subject GSK206136 Unknown 2 mg —
Subject GSK206136 Unknown 10 mg —
Subject GSK206136 Unknown 50 mg —
Subject GSK206136 Unknown 100 mg —